Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

403 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
Purroy N, Tong YE, Lemvigh CK, Cieri N, Li S, Parry EM, Zhang W, Rassenti LZ, Kipps TJ, Slager SL, Kay NE, Lesnick C, Shanafelt TD, Ghia P, Scarfò L, Livak KJ, Kharchenko PV, Neuberg DS, Olsen LR, Fan J, Gohil SH, Wu CJ. Purroy N, et al. Among authors: ghia p. Blood. 2022 Apr 7;139(14):2252-2256. doi: 10.1182/blood.2021013926. Blood. 2022. PMID: 35020831 Free PMC article. No abstract available.
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F. Young E, et al. Among authors: ghia p. Leukemia. 2017 Jul;31(7):1547-1554. doi: 10.1038/leu.2016.359. Epub 2016 Nov 28. Leukemia. 2017. PMID: 27890934 Free PMC article.
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.
Farinello D, Wozińska M, Lenti E, Genovese L, Bianchessi S, Migliori E, Sacchetti N, di Lillo A, Bertilaccio MTS, de Lalla C, Valsecchi R, Gleave SB, Lligé D, Scielzo C, Mauri L, Ciampa MG, Scarfò L, Bernardi R, Lazarevic D, Gonzalez-Farre B, Bongiovanni L, Campo E, Cerutti A, Ponzoni M, Pattini L, Caligaris-Cappio F, Ghia P, Brendolan A. Farinello D, et al. Among authors: ghia p. Nat Commun. 2018 May 3;9(1):1787. doi: 10.1038/s41467-018-04150-7. Nat Commun. 2018. PMID: 29725010 Free PMC article.
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, Papakonstantinou N, Scarfò L, Agathangelidis A, Fonte E, Ranghetti P, Nenou A, Xochelli A, Coscia M, Tedeschi A, Stavroyianni N, Muzio M, Stamatopoulos K, Ghia P. Gounari M, et al. Among authors: ghia p. Leukemia. 2019 Apr;33(4):1030-1051. doi: 10.1038/s41375-018-0335-2. Epub 2019 Jan 3. Leukemia. 2019. PMID: 30607020 No abstract available.
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. Scheffold A, et al. Among authors: ghia p. Blood. 2019 Aug 8;134(6):534-547. doi: 10.1182/blood.2018881029. Epub 2019 Apr 22. Blood. 2019. PMID: 31010847 Free PMC article.
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Coutre SE, et al. Among authors: ghia p. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. Blood Adv. 2019. PMID: 31196847 Free PMC article. Clinical Trial.
Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
Chartomatsidou E, Ntoufa S, Kotta K, Rovida A, Akritidou MA, Belloni D, Ferrero E, Trangas T, Stavroyianni N, Anagnostopoulos A, Rosenquist R, Ghia P, Papakonstantinou N, Stamatopoulos K. Chartomatsidou E, et al. Among authors: ghia p. Blood Adv. 2019 Jun 25;3(12):1891-1896. doi: 10.1182/bloodadvances.2018030262. Blood Adv. 2019. PMID: 31227476 Free PMC article.
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, Bairey O, Hillmen P, Coutre SE, Devereux S, Grosicki S, McCarthy H, Simpson D, Offner F, Moreno C, Dai S, Lal I, Dean JP, Kipps TJ. Burger JA, et al. Among authors: ghia p. Leukemia. 2020 Mar;34(3):787-798. doi: 10.1038/s41375-019-0602-x. Epub 2019 Oct 18. Leukemia. 2020. PMID: 31628428 Free PMC article. Clinical Trial.
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Vardi A, Vlachonikola E, Papazoglou D, Psomopoulos F, Kotta K, Ioannou N, Galigalidou C, Gemenetzi K, Pasentsis K, Kotouza M, Koravou E, Scarfó L, Iskas M, Stavroyianni N, Ghia P, Anagnostopoulos A, Kouvatsi A, Ramsay AG, Stamatopoulos K, Chatzidimitriou A. Vardi A, et al. Among authors: ghia p. Clin Cancer Res. 2020 Sep 15;26(18):4958-4969. doi: 10.1158/1078-0432.CCR-19-3827. Epub 2020 Jul 2. Clin Cancer Res. 2020. PMID: 32616500
403 results